STOCK TITAN
  1. Home
  2. Sec-filings
  3. MIRM
  4. [Form 4] Mirum Pharmaceuticals, Inc. Insider Trading Activity

Mirum Pharmaceuticals (MIRM) CFO sells 5,000 shares under 10b5-1 plan

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Mirum Pharmaceuticals’ chief financial officer Eric Bjerkholt sold 5,000 shares of common stock in open-market transactions. The sales occurred on July 6, 2026 at prices reported between about $121.13 and $124.94 per share, pursuant to a pre-arranged Rule 10b5-1 plan. Following these transactions, he continues to own 42,181 shares directly.

Positive

  • None.

Negative

  • None.
Insider BJERKHOLT ERIC
Role CHIEF FINANCIAL OFFICER
Sold 5,000 shs ($611K)
Type Security Shares Price Value
Sale Common Stock 3,124 $121.67 $380K
Sale Common Stock 1,048 $122.43 $128K
Sale Common Stock 528 $123.84 $65K
Sale Common Stock 300 $124.94 $37K
Holdings After Transaction: Common Stock — 44,057 shares (Direct, null)
Footnotes (1)
  1. Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on March 9, 2026. . The weighted average sale price for the transaction reported was $121.67, and the range of prices were between $121.13 and $122.13. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. . The weighted average sale price for the transaction reported was $122.43, and the range of prices were between $122.235 and $123.10. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. . The weighted average sale price for the transaction reported was $123.84, and the range of prices were between $123.285 and $124.27. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
Total shares sold 5,000 shares Common stock sold in open-market transactions on July 6, 2026
Sale price $124.94 per share One of the reported open-market sales of common stock
Sale price $123.84 per share One of the reported open-market sales of common stock
Sale price $122.43 per share One of the reported open-market sales of common stock
Sale price $121.67 per share Weighted average sale price for one transaction batch
Shares held after transactions 42,181 shares Direct ownership of Mirum common stock following reported sales
Largest single sale block 3,124 shares Open-market sale at $121.67 per share
Net share activity 5,000 shares sold Net-sell direction from transaction summary
Rule 10b5-1 Plan regulatory
"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on March 9, 2026."
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
weighted average sale price financial
"The weighted average sale price for the transaction reported was $121.67"
price ranges financial
"the range of prices were between $121.13 and $122.13"
common stock financial
"security_title": "Common Stock""
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →

FAQ

What did Mirum Pharmaceuticals (MIRM) CFO Eric Bjerkholt report in this Form 4?
He reported selling 5,000 shares of Mirum Pharmaceuticals common stock in open-market transactions. The trades were executed on July 6, 2026, and were made under a pre-arranged Rule 10b5-1 trading plan disclosed in the filing’s footnotes.

How many Mirum Pharmaceuticals (MIRM) shares did the CFO sell and at what prices?
Eric Bjerkholt sold a total of 5,000 common shares. Individual transactions were priced around $124.94, $123.84, $122.43, and $121.67 per share, with footnotes providing weighted average prices and price ranges for several of the sale batches.

Does Mirum Pharmaceuticals (MIRM) CFO Eric Bjerkholt still hold shares after these sales?
Yes. After the reported open-market sales, he directly holds 42,181 shares of Mirum Pharmaceuticals common stock. The Form 4 shows this as his post-transaction ownership, indicating the sale represented only a portion of his total direct holdings.

Were the Mirum Pharmaceuticals (MIRM) CFO share sales discretionary or pre-planned?
The filing states the transactions occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on March 9, 2026. Such plans are pre-arranged trading programs, which typically automate trades according to preset instructions rather than discretionary market timing.

What additional pricing detail does the Mirum Pharmaceuticals (MIRM) Form 4 provide?
Footnotes disclose weighted average sale prices of $121.67, $122.43 and $123.84, with price ranges like $121.13–$122.13 and $123.285–$124.27. The Form 4 notes that detailed breakdowns by exact price level are available upon request to the issuer or SEC staff.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
BJERKHOLT ERIC
(Last)(First)(Middle)
C/O MIRUM PHARMACEUTICALS, INC.
989 E HILLSDALE BLVD., SUITE 300
(Street)
FOSTER CITY CALIFORNIA 94404
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Mirum Pharmaceuticals, Inc. [ MIRM ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
CHIEF FINANCIAL OFFICER
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/06/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock07/06/2026S(1)3,124D$121.67(2)44,057D
Common Stock07/06/2026S(1)1,048D$122.43(3)43,009D
Common Stock07/06/2026S(1)528D$123.84(4)42,481D
Common Stock07/06/2026S(1)300D$124.9442,181D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on March 9, 2026.
2. . The weighted average sale price for the transaction reported was $121.67, and the range of prices were between $121.13 and $122.13. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
3. . The weighted average sale price for the transaction reported was $122.43, and the range of prices were between $122.235 and $123.10. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
4. . The weighted average sale price for the transaction reported was $123.84, and the range of prices were between $123.285 and $124.27. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
/s/ Judit Ryvkin, Attorney-in-Fact07/08/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR